Acquired thrombocytopenia

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another …

This phase 2 trial tests a bone marrow transplant using lower doses of chemotherapy and radiation to prepare the body, along with a drug called cyclophosphamide after transplant to prevent graft-versus-host disease. It enrolls 60 people with severe aplastic anemia or related bone…

This study tests whether a single infusion of umbilical cord blood can safely raise platelet levels in cancer patients whose platelets have dropped due to chemotherapy or other cancer treatments. Researchers will enroll 25 people aged 12 to 65 and monitor their blood counts for 2…

This study is collecting information from 40 patients with a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have been treated with daratumumab. The goal is to see how well daratumumab works and how safe it is for patients whose disease d…

This study tests a new drug called romiplostim N01, given as a weekly shot, against a standard daily shot (rhIL-11) for cancer patients whose platelet counts drop due to treatment. About 88 adults with various cancers and low platelets will be randomly assigned to one of the two …

This phase 2 trial is testing whether the drug hetrombopag can prevent chemotherapy-induced thrombocytopenia (low platelet counts) in people with gastrointestinal tumors. The study will enroll 40 patients who had low platelets in a previous chemo cycle. Participants take hetrombo…

This study tests a single injection of PN20, a lab-made protein, to see if it can safely raise platelet counts in adults with chronic liver disease who have low platelets and are scheduled for a minor procedure. About 54 participants will receive either PN20 or a placebo. The mai…

This study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …

This early-stage trial is testing a single infusion of cells from umbilical cord blood (called XJ-MK-002) in 16 cancer patients whose platelet counts have dropped due to chemotherapy or other cancer treatments. The main goal is to see if the treatment is safe and tolerable, and t…

This study tests a drug called QL0911 for people whose platelet levels drop too low due to cancer treatment. Low platelets can delay chemotherapy and cause bleeding risks. The trial will compare QL0911 to a placebo in 235 adults aged 18-75 to see if it safely raises platelet coun…

This study looks at whether a specific gene, TNFAIP3, is linked to immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood clotting disorder. Researchers will compare genetic data from 400 people with iTTP and healthy volunteers to see if gene variations affect d…

This study looks for substances in the blood that might be linked to fatigue in people with low platelet counts (thrombocytopenia). Researchers think a protein called BDNF, which is stored in platelets, could play a role. They will measure BDNF levels in 280 patients and healthy …

This study reviews medical records from over 1,200 people with immune thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. The goal is to understand long-term health problems, such as heart disease and thinking issues, that survivors face. By an…